Vol. 4 No. 9 (2024)
Reimbursement Reviews

Cemiplimab (Libtayo)

decorative image of the issue cover

Published September 18, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cemiplimab for injection (Libtayo), 350 mg/7 mL (50 mg/mL), single-use vial for IV infusion.
  • Indication: In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non–small cell lung cancer whose tumours have no EGFR, ALK, or ROS1 aberrations and is:
    • locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or
    • metastatic non–small cell lung cancer.